Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-α

Blood

Volumn 91, Issue 8, 1998, Pages 3017-3027

  Grimley, Philip M ^a   Fang, Hui ^b   Rui, Hallgeir ^b   Petricoin III, Emanuel F ^b   Ray, Subhransu ^b   Dong, Fan ^b   Fields, Karen H ^b   Hu, Renqiu ^b   Zoon, Kathryn C ^b   Audet, Susette ^b   Beeler, Judy ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AURINTRICARBOXYLIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL CYCLE; CELL GROWTH; DNA BINDING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 0032523158     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.3017.3017_3017_3027     Document Type: Article

References (78)

1. Hanson MN, Morrison VA, Peterson BA, Stieglbauer KT, Kubic VL, McCormick SR, McGlennen RC, Manivel JC, Brunning RD, Litz CE: Posttransplant T-cell lymphoproliferative disorders - An aggressive, late complication of solid-organ transplantation. Blood 88:3626, 1996
2. Tossing G: Immunodeficiency and its relation to lymphoid and other malignancies. Ann Hematol 73:163, 1996
3. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA: Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 97:14, 1994
4. Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken MM, Borden EC: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336, 1992
5. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P: Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 28:1300, 1968
6. nA and protein kinase systems in wild-type and interferon-resistam Daudi cells. Eur J Biochem 126:333, 1982
7. Kumar R, Korutla L, Zhang K: Cell cycle-dependent modulation of alpha-interferon-inducible gene expression and activation of signaling components in Daudi cells. J Biol Chem 269:25437, 1994
8. Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffman I, Reed SI, Kimchi A: Alpha Interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol Cell Biol 16:3934, 1996
9. Tovey MG, Dron M, Mogensen KE, Lebleu B, Mechti N, Begonlours-Guymarho J: Isolation of Daudi cells with reduced sensitivity to interferon. II. On the mechanisms of resistance. J Gen Virol 64:2649, 1983
10. 1 arrest. Nature 313:597, 1985
11. McMahon M, Stark GR, Kerr IM: Interferon-induced gene expression in wild-type and interferon-resistant human lymphoblastoid (Daudi) cells. J Virol 57:362, 1986
12. Guille MJ, Laxton CD, Rutherford MN, Williams BR, Kerr IM: Functional differences in the promoters of the interferon-inducible (2′-5′)A oligoadenylate synthetase and 6-16 genes in interferon-resistant Daudi cells. Eur J Biochem 219:5, 1994
13. Darnell JE Jr, Kerr IM, Stark GR: Jak STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415, 1994
14. Briscoe J, Guschin D, Rogers NC, Watling D, Muller M, Horn F, Heinrich P, Stark GR, Kerr IM: JAKs, STATs and signal transduction in response to the interferons and other cytokines. Phil Trans R Soc Lond B Biol Sci 351:167, 1996
15. Ihle JN: STATs: Signal transducers and activators of transcription. Cell 84:331, 1996
16. Larner AC, David M, Feldman GM, Igarashi K, Hacken RH, Webb DS, Sweitzer SM, Petricoin EF 3rd, Finbloom DS: Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science 261:1730, 1993
17. Tanaguchi T: Cytokine signaling through nonreceptor protein tyrosine kinases. Science 268:251, 1995
18. David M, Romero G, Zhang Z, Dixon JE, Larner AC: In vitro activation of the transcription factor ISGF3 by interferon alpha involves a membrane-associated tyrosine phosphatase and tyrosine kinase. J Biol Chem 268:6593, 1993
19. Novick D, Cohen B, Rubinstein M: The human α/β receptor: Characterization and molecular cloning. Cell 77:391, 1994
20. Colamonici OR, Platanias LC, Domanski P, Handa R, Gilmour KC, Diaz MO, Reich N, Pitha-Rowe P: Transmembrane signaling by the alpha subunit of the type I interferon receptor is essential for activation of the JAK kinases and the transcriptional factor ISGF3. J Biol Chem 270: 8188, 1995
21. Yan H, Krishnan K, Lim JT, Contillo LG, Krolewski JJ: Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction. Mol Cell Biol 16:2074, 1996
22. Velazquez L, Mogensen KE, Barbieri G, Fellous M, Uze G, Pellegrini S: Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction. J Biol Chem 270:3327, 1995
23. Gauzzi MC, Velazquez L, McKendry R, Mogensen KE, Fellous M, Pellegrini S: Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J Biol Chem 271:20494, 1996
24. Meraz MA, White JM, Sheehan KCF, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD: Targeted disruption of the Stat 1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431, 1996
25. Durbin JE, Hackenmiller R, Simon MC, Levy DE: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443, 1996
26. Briscoe J, Rogers NC, Witthuhn BA, Watling D, Harpur AG, Wilks AF, Stark GR. Ihle JN, Kerr IM: Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO J 15: 799, 1996
27. Schindler C, Fu XY, Improta T, Aebersold R, Darell JE Jr: Proteins of transcription factor ISGF-3: One gene encodes the 91- and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA 89:7836, 1992
28. Yan R, Qureshi S, Zhong Z, Wen Z, Darnell JE Jr: The genomic structure of the STAT genes: Multiple exons in coincident sites in Stat1 and Stat2. Nucleic Acids Res 23:459, 1995
29. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr: Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 93:7673, 1996
30. Yan H, Krishnan K, Greenlund AC, Gupta S, Lim JT, Schreiber RD, Schindler CW, Krolewski JJ: Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. EMBO J 15:1064, 1996
31. Qureshi SA, Leung S, Kerr IM, Stark GR, Darnell JE Jr: Function of Stat2 protein in transcriptional activation by alpha interferon. Mol Cell Biol 16:288, 1996
32. Heim MH, Kerr IM, Stark GR, Darnell JE Jr: Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 267:13, 1995
33. David M, Grimley PM, Finbloom DS, Larner AC: A nuclear tyrosine phosphatase downregulates interferon-induced gene expression. Mol Cell Biol 13:7515, 1993
34. David M: Transcription factors in interferon signaling. Pharm Ther 65:149, 1995
35. Haspel RL, Salditt-Georgieff M, Darnell JE Jr: The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 15:6262, 1996
36. Zhang X, Blenis J, Heng-Chun L, Schindler C, Chen-Kiang S: Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 267:1990, 1995
37. Wen Z, Zhong Z, Darnell JE Jr: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82:241, 1995
38. Li X, Leung S, Qureshi S, Darnell JE Jr, Stark GR: Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J Biol Chem 271:5790, 1996
39. Kassler DS, Veals SA, Fu XY, Levy DE: Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev 4:1753, 1990
40. Veals SA, Santa Maria T, Levy DE: Two domains of ISGF3 gamma that mediate protein-DNA and protein-protein interactions during transcription factor assembly contribute to DNA-binding specificity. Mol Cell Biol 13:196, 1993
41. Rubin YR, Gupta SL: Interferon-induced proteins in human fibroblasts and development of the antiviral state. J Virol 34:446, 1980
42. Shulman S, Revel M: Interferon-dependent induction of mRNA activity for (2′-5′) oligo-isoadenylate synthetase. Nature 288:98, 1980
43. West DK, Ball LA: Induction and maintenance of 2′5′-oligoadenylate synthetase, in interferon-treated chicken embryo cells. Mol Cell Biol 2:1436, 1982
44. Mogensen KE, Bandu M-T: Kinetic evidence for an activation step following binding of human interferon α2 to the membrane receptors of Daudi cells. Eur J Biochem 134:355, 1983
45. Kirken RA, Malabarba MG, Xu J, Liuw X, Farrar WL, Hennighausen L, Lamer AC, Grimley PM, Rui H: Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J Biol Chem 272:15459, 1997
46. Balint E, Aszalos A, Grimley PM: Alpha interferon accelerates lateral diffusion of Daudi cell surface differentiation antigens: Measurement by fluorescence redistribution after photobleaching. Biochem Biophys Res Commun 157:808, 1988
47. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K: An improved colorimetric assay for interleukin 2. J Immunol Methods 93:157, 1986
48. Albrecht P, Heramann K, Burns GR: Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 3:251, 1981
49. Reed LJ, Muench H: A simple method of estimating fifty percent endpoints. Am J Hygiene 27:493, 1938
50. Sullivan JL, Barry DW, Lucas SJ, Albrecht P: Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes. J Exp Med 142:773, 1975
51. Zoon KC, Zur Nedden D, Hu R, Arnheiter H: Analysis of the steady state binding, internalization, and degradation of human interferon-alpha2. J Biol Chem 261:4993, 1986
52. Hu R, Can Y, Liu J, Miller D, Zoon KC: Evidence for multiple binding sites for several components of human lymphoblastoid interferon-alpha. J Biol Chem 268:12591, 1993
53. Nakagawa Y, Petricoin EF 3rd, Akai H, Grimley PM, Rupp B, Lamer AC: Interferon-alpha-induced gene expression: Evidence for a selective effect of ouabain on activation of the ISGF3 transcription complex. Virology 190:210, 1992
54. Bovolenta C, Driggers PH, Marks MS, Medin JA, Politis AD, Vogel SN, Levy DE, Sakaguchi K, Appella E, Coligan JE, Ozato K: Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc Natl Acad Sci USA 91:5046, 1994
55. Wilson KC, Finbloom DS: Interferon gamma rapidly induces in human monocytes a DNA-binding factor that recognizes the gamma response region within the promoter of the gene for the high-affinity Fc gamma receptor. Proc Natl Acad Sci USA 89:11964, 1992
56. Reich N, Evans B, Levy D, Fahey D, Knight E Jr, Darnell JE Jr: Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proc Natl Acad Sci USA 84:6394, 1987
57. Kim TK, Maniatis T: Regulation of interferon-γ-activated STAT1 by the ubiquitin-proteosome pathway. Science 273:1717, 1996
58. Thornton AM, Ogryzko VV, Dent A, Sharf R, Levi BZ, Kanno Y, Staudt LM, Howard BH, Ozato K: A dominant negative mutant of an IFN regulatory factor family protein inhibits both type I and type II IFN-stimulated gene expression and antiproliferative activity of IFNs. J Immunol 157:5145, 1996
59. Kimura T, Nakayama K, Penninger J, Kitagawa M, Harada H, Matsuyama T, Tanaka N, Kamijo R, Vilcek J, Mak TW, Taniguchi T: Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 264:1921, 1994
60. Horvath CM, Darnell JE Jr: The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 protein. J Virol 70:647, 1996
61. Tamaoki T: Use and specificity of staurosporine, UCN-O1 and Calphostin C as protein kinase inhibitors. Methods Enzymol 201:340, 1991
62. Kessler DS, Levy DE: Protein kinase activity required for an early step in interferon-alpha signaling. J Biol Chem 266:231, 1991
63. Exley R, Gordon J, Clemens MJ: Induction of B-cell differentiation antigens in interferon-or phorbol ester-treated Daudi cells is impaired by inhibitors of ADP-ribosyltransferase. Proc Natl Acad Sci USA 84:6467, 1987
64. Schaffer FM, Benedict SH, Petsche D, Lau A, Williams BR, Mills GB, Gelfand EW: Interferon and phorbol esters down-regulate sIgM expression by independent pathways. J Cell Physiol 134:245, 1988
65. Guo Z, Weinstein MJ, Phillips MD, Kroll MH: M(r) 6,400 aurin tricarboxylic acid directly activates platelets. Thromb Res 71:77, 1993
66. Gan YX, Weaver JL, Pine PS, Zoon KC, Aszalos A: Aurin tricarboxylic acid, the anti-AIDS compound, prevents the binding of interferon-alpha to its receptor. Biochem Biophys Res Commun 172: 1298, 1990
67. Das T, Schuster A, Schneider-Schaulies S, Banerjee AK: Involvement of cellular casein kinase II in the phosphorylation of measles virus P protein: Identification of phosphorylation sites. Virology 211:218, 1995
68. Vainionpaa R, Hyypia T, Akerman KE: Early signal transduction in measles virus-infected lymphocytes is unaltered, but second messengers activate virus replication. J Virol 65:6743, 1991
69. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E: Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 14:2666, 1996
70. Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH: STAT3 as an adapter to couple phosphaidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 276:1418, 1997
71. David M, Zhou G, Pine R, Dixon JE, Lamer AC: The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon alpha/beta-induced gene expression. J Biol Chem 271:15862, 1996
72. Petricoin E 3rd, David M, Igarashi K, Benjamin C, Ling L, Goelz S, Finbloom DS, Larner AC: Inhibition of alpha interferon but not gamma interferon signal transduction by phorbol esters is mediated by a tyrosine phosphatase. Mol Cell Biol 16:1419, 1996
73. Apirion D, Dohner D: Aurintricarboxylic acid a non-antibiotic organic molecule that inhibits protein synthesis, in Corcoran JW, Hahn FE (eds): Antibiotics, vol III. New York, NY, Springer-Verlag, 1975, p 327
74. Gilbert M, Brigido L, Muller WE, Hansen JE, Ezekowitz RA, Mills J: Screening for inhibitors of HIV gp120-CD4 binding using an enzyme-linked immunoabsorbent assay. J Virol Methods 42:1, 1993
75. Pfeffer LM, Stebbing N, Donner DB: Cytoskeletal association of human α-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells. Proc Natl Acad Sci USA 84:3249, 1987
76. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH: A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 12:3297, 1993
77. Pestka S, Langer JA, Zoon KC, Samuel CE: Interferons and their actions. Annu Rev Biochem 56:727, 1987
78. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272:719, 1996